In November 2022, the U.S. Food and Drug Administration approved teplizumab, a CD3- directed monoclonal antibody and the first drug

In a new feature at the 83 Scientific Sessions, six diabetes innovators will have the opportunity to present their ideas

Genome-wide association studies (GWAS) and polygenic risk scores (PRS) are two significant concepts in the field of genetics that have

“First-of-its-Kind Data Underscore Importance of Early Use of Drug Therapy as a Primary Prevention,Especially for Those Living with Diabetes” Today,

As part of the session “Efficacy. Engagement, and Sustainability of Dietary Management Options in Type 2 Diabetes – Time for

As part of the session “Efficacy. Engagement, and Sustainability of Dietary Management Options in Type 2 Diabetes – Time for

As part of the session “Real-World Hypoglycaemia in Older Adults with Diabetes” This Paper Was Presented By Drs Emily Tang,

As part of the session “Real-World Hypoglycaemia in Older Adults with Diabetes” This Paper Was Presented By Drs Gemma A.

Cardiovascular concerns are on the rise for people with diabetes, both in terms of acute and chronic complications, and a

A coordinated paradigm designed to overcome patient-, clinic-, and system-level barriers to care can significantly increase the prescribing of evidence-based